

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **GARVEY et al**

Application No.: **09/478,222**

Group Art Unit: **1627**

Filed: **January 5, 2000**

Examiner: **B. Celsa**

For: **Nitrosated and Nitrosylated Alpha-Adrenergic Receptor
Antagonist Compounds, Compositions and Their Uses**

Attorney Docket No.: **102258.346**

Assistant Commissioner of Patents
Washington, DC 20231

1627-4
RECEIVED
NOV 05 2001
TECH CENTER 1600/2900

#14
5/10/02
1-21-02

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449 Form. A copy of each of the documents is submitted herewith.

The submission of this Information Disclosure Statement does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art.

This Information Disclosure Statement is being filed after a first office action, but before a final office action or notice of allowance. Accordingly, the Commissioner is authorized to charge the fee of \$180 to Deposit Account No. 08-0219. The Commissioner is authorized to charge any other necessary fees or credit any overpayments to Deposit Account No. 08-0219 to maintain the pendency of the application.

Applicants respectfully request that the Examiner return an initialed copy of the PTO-1440 Form with the next communication from the PTO.

Respectfully submitted,

Edward D. Grieff
Registration No. 38,898

Date: November 1, 2001

HALE and DORR LLP
1455 Pennsylvania Avenue, NW
Washington, DC 20004
Phone: (202) 942-8400

11/02/2001 AHONDAF1 00000072 080219 09478222

01 FC:126 180.00 CH